

Petr Widimsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/328566/publications.pdf>

Version: 2024-02-01

310
papers

60,999
citations

9756

73
h-index

871

243
g-index

321
all docs

321
docs citations

321
times ranked

39598
citing authors

#	ARTICLE	IF	CITATIONS
1	Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 186-196.	1.5	8
2	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 462-473.	1.4	8
3	4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1-14.	1.2	114
4	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS120010390.	1.4	4
5	Patient characteristics, treatment strategy, outcomes, and hospital costs of acute coronary syndrome: 3 years of data from a large high-volume centre in Central Europe. <i>European Heart Journal Supplements</i> , 2022, 24, B3-B9.	0.0	3
6	Direct transfer of acute stroke patients to angiography suites equipped with flat-detector computed tomography: literature review and initial single-centre experience. <i>European Heart Journal Supplements</i> , 2022, 24, B42-B47.	0.0	1
7	Clinical and radiological factors predicting stroke outcome after successful mechanical intervention in anterior circulation. <i>European Heart Journal Supplements</i> , 2022, 24, B48-B52.	0.0	6
8	Stroke thrombectomy (± thrombolysis), and not thrombolysis alone, should be the gold standard for stroke treatment. <i>EuroIntervention</i> , 2022, 17, e1367-e1368.	1.4	1
9	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	1.4	6
10	The relationship between symptom onset-to-needle time and ischemic outcomes in patients with acute myocardial infarction treated with primary PCI. <i>Journal of Cardiology</i> , 2022, 79, 626-633.	0.8	0
11	Interdisciplinary management of acute ischaemic stroke: Current evidence training requirements for endovascular stroke treatment: Position Paper from the ESC Council on Stroke and the European Association for Percutaneous Cardiovascular Interventions with the support of the European Board of Neurointervention. <i>European Heart Journal</i> , 2021, 42, 298-307.	1.0	18
12	Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. <i>ESC Heart Failure</i> , 2021, 8, 1924-1932.	1.4	8
13	Risk of a coronary event in patients after ischemic stroke or transient ischemic attack. <i>Anatolian Journal of Cardiology</i> , 2021, 25, 152-155.	0.5	8
14	Jiri Widimsky MD. <i>European Heart Journal</i> , 2021, 42, 1285-1286.	1.0	0
15	Stable Clinical Outcomes When a Stroke Thrombectomy Program Is Started in an Experienced Cardiology Cath Lab. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 785-792.	1.1	9
16	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <i>Heart</i> , 2021, 107, 1130-1137.	1.2	6
17	MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty. <i>Journal of Personalized Medicine</i> , 2021, 11, 508.	1.1	17
18	The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUEâ€17 trial subanalysis. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 2645-2654.	0.8	5

#	ARTICLE	IF	CITATIONS
19	Modified Strategies for Invasive Management of Acute Coronary Syndrome during the COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , 2021, 10, 24.	1.0	11
20	Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 682-692.	0.8	15
21	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 296-307.	0.8	28
22	Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 330-337.	2.9	24
23	Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 279-287.	1.1	34
24	Both selective and nonselective His bundle, but not myocardial, pacing preserve ventricular electrical synchrony assessed by ultra-high-frequency ECG. <i>Heart Rhythm</i> , 2020, 17, 607-614.	0.3	36
25	History of cardiovascular research at the Charles University. <i>European Heart Journal Supplements</i> , 2020, 22, F1-F5.	0.0	0
26	Current cardiovascular research at the Charles University: the "PRAGUE" trials and beyond. <i>European Heart Journal Supplements</i> , 2020, 22, F6-F13.	0.0	0
27	The prognostic significance of periprocedural infarction in the era of potent antithrombotic therapy. The PRAGUE-18 substudy. <i>International Journal of Cardiology</i> , 2020, 319, 1-6.	0.8	0
28	Endovascular thrombectomy 2020: open issues. <i>European Heart Journal Supplements</i> , 2020, 22, M13-M18.	0.0	3
29	LUCAS II Device for Cardiopulmonary Resuscitation in a Nonselective Out-of-Hospital Cardiac Arrest Population Leads to Worse 30-Day Survival Rate Than Manual Chest Compressions. <i>Journal of Emergency Medicine</i> , 2020, 59, 673-679.	0.3	5
30	Czech Republic and low COVID-19 mortality in the heart of Europe: possible explanations. <i>European Heart Journal</i> , 2020, 41, 3876-3879.	1.0	6
31	Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2020, 396, 830-838.	6.3	44
32	Otto Klein from Prague University Hospital performed the world first diagnostic cardiac catheterization in 11 Czech patients in 1929. <i>European Heart Journal</i> , 2020, 41, 1323-1325.	1.0	0
33	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. <i>European Heart Journal</i> , 2020, 41, 3255-3268.	1.0	49
34	Heart rate as an independent predictor of long term mortality of acute heart failure patients in sinus rhythm according to their ejection fraction: data from the AHEAD registry. <i>European Journal of Internal Medicine</i> , 2020, 78, 88-94.	1.0	2
35	Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3122-3135.	1.2	349
36	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1841-1854.	1.6	96

#	ARTICLE	IF	CITATIONS
37	Bioresorbable scaffold implantation in STEMI patients: 5Âyears imaging subanalysis of PRAGUE-19 study. <i>Journal of Translational Medicine</i> , 2020, 18, 33.	1.8	8
38	Age-Related Variations in Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1869-1877.	1.2	42
39	The potential value of histological analysis of thrombi extracted through mechanical thrombectomy during acute ischemic stroke treatment. <i>Anatolian Journal of Cardiology</i> , 2020, 23, 254-259.	0.5	6
40	Stent thrombosis during and after acute coronary syndromes: patient-related factors and operator-related factors. <i>Anatolian Journal of Cardiology</i> , 2020, 24, 274-279.	0.5	2
41	Left atrial appendage closure â€“ ready for widespread clinical use?. <i>EuroIntervention</i> , 2020, 16, e701-e702.	1.4	2
42	Clinical Features and Outcomes of Patients With Malignancy and Takotsubo Syndrome: Observations From the International Takotsubo Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010881.	1.6	63
43	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <i>Gastroenterology</i> , 2019, 157, 682-691.e2.	0.6	299
44	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3271-3280.	1.2	95
45	Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019, 157, 403-412.e5.	0.6	108
46	Clinical Predictors and Prognostic Impact of Recovery of Wall Motion Abnormalities in Takotsubo Syndrome: Results From the International Takotsubo Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e011194.	1.6	27
47	Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. <i>Circulation</i> , 2019, 139, 413-415.	1.6	75
48	Prediction of shortâ€and longâ€term mortality in takotsubo syndrome: the InterTAK Prognostic Score. <i>European Journal of Heart Failure</i> , 2019, 21, 1469-1472.	2.9	20
49	Ticagrelor in Patients with Stable Coronary Disease and Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 1309-1320.	13.9	255
50	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019, 140, 1451-1459.	1.6	36
51	A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI) Tj ETQq1 1 0.784314 rg51 /Overl	1.0	1
52	Hyperuricemia treatment in acute heart failure patients does not improve their longâ€term prognosis: A propensity score matched analysis from the AHEAD registry. <i>Clinical Cardiology</i> , 2019, 42, 720-727.	0.7	12
53	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 171-180.	1.4	46
54	Five-year outcomes in cardiac surgery patients with atrial fibrillation undergoing concomitant surgical ablation versus no ablation. The long-term follow-up of the PRAGUE-12 Study. <i>Heart Rhythm</i> , 2019, 16, 1334-1340.	0.3	23

#	ARTICLE	IF	CITATIONS
55	Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry. <i>European Heart Journal</i> , 2019, 40, 2142-2151.	1.0	79
56	Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 906-914.	1.2	14
57	Prevalence and predictors of coronary artery disease in patients undergoing carotid artery stenting. <i>Coronary Artery Disease</i> , 2019, 30, 204-210.	0.3	9
58	The year in cardiology 2018: acute coronary syndromes. <i>European Heart Journal</i> , 2019, 40, 271-282.	1.0	11
59	Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. <i>Journal of the American College of Cardiology</i> , 2019, 73, 121-130.	1.2	69
60	Incidence, treatment strategies and outcomes of acute coronary syndrome with and without ongoing myocardial ischaemia: results from the CZECH-3 registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 687-694.	0.4	6
61	Electrocardiogram changes due to myocardial infarction in a patient with selective His bundle pacing. <i>Kardiologia Polska</i> , 2019, 77, 237-237.	0.3	0
62	Clinical outcomes of acute ischemic stroke patients treated by direct catheter-based thrombectomy depending on their baseline characteristics. <i>Cor Et Vasa</i> , 2018, 60, e30-e34.	0.1	4
63	The role of cardiologists in stroke prevention and treatment: position paper of the European Society of Cardiology Council on Stroke. <i>European Heart Journal</i> , 2018, 39, 1567-1573.	1.0	21
64	Enteric-coated aspirin in cardiac patients: Is it less effective than plain aspirin?. <i>Cor Et Vasa</i> , 2018, 60, e165-e168.	0.1	10
65	Trends in the treatment and outcomes of elderly patients with acute coronary syndrome: Results from the CZECH registries. <i>Cor Et Vasa</i> , 2018, 60, e66-e69.	0.1	1
66	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). <i>European Heart Journal</i> , 2018, 39, 763-816.	1.0	2,305
67	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2018, 39, 119-177.	1.0	7,100
68	The mortality benefit seen with the newer more potent oral P2Y12 inhibitors prasugrel and ticagrelor over clopidogrel is dependent on the underlying risk: A class effect as suggested by a meta-regression analysis. <i>Cor Et Vasa</i> , 2018, 60, e127-e132.	0.1	2
69	1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor. <i>Journal of the American College of Cardiology</i> , 2018, 71, 371-381.	1.2	139
70	Optical coherence tomography in STEMI with bioresorbable scaffold: possible cause of coronary flow impairment? A sub-study from the Prague 19 trial. <i>Heart and Vessels</i> , 2018, 33, 1282-1287.	0.5	1
71	Long-Term Prognosis of Patients With Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2018, 72, 874-882.	1.2	224
72	Degenerative changes and immune response after transcatheter aortic valve implantation. Comparison with surgical aortic valve replacement. <i>Journal of Cardiology</i> , 2017, 69, 483-488.	0.8	8

#	ARTICLE	IF	CITATIONS
73	Worse prognosis of real-world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX-AHF trial. <i>ESC Heart Failure</i> , 2017, 4, 8-15.	1.4	5
74	Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension. <i>Journal of Hypertension</i> , 2017, 35, 1093-1099.	0.3	25
75	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	0.8	133
76	Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 198-213.	1.4	18
77	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	13.9	1,745
78	Mechanical circulatory support: harm without benefit? Fascinated by devices, cardiologists may lose common sense. <i>European Heart Journal</i> , 2017, 38, 3535-3537.	1.0	3
79	Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	9
80	Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study). <i>American Heart Journal</i> , 2017, 183, 108-114.	1.2	49
81	Antithrombotic therapy of patients with atrial fibrillation discharged after major non-cardiac surgery. 1-year follow-up. Sub-analysis of PRAGUE 14 study. <i>PLoS ONE</i> , 2017, 12, e0177519.	1.1	0
82	Feasibility and safety of direct catheter-based thrombectomy in the treatment of acute ischaemic stroke. Cooperation among cardiologists, neurologists and radiologists. Prospective registry PRAGUE-16. <i>EuroIntervention</i> , 2017, 13, 131-136.	1.4	20
83	Acute ischaemic stroke in atrial fibrillation: worse outcomes unrelated to treatment methods. <i>EuroIntervention</i> , 2017, 13, 905-906.	1.4	2
84	When will acute stroke interventions be as widely available as primary PCI?. <i>EuroIntervention</i> , 2017, 13, 1269-1272.	1.4	1
85	The influence of age on clinical outcomes in patients treated with the resolute zotarolimus-eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 253-261.	0.7	8
86	How many years it will take to implement the new stroke guidelines for the benefit of all suitable patients with acute ischemic stroke in Europe?. <i>Cor Et Vasa</i> , 2016, 58, e212-e214.	0.1	0
87	Is bivalirudin just an expensive heparin?: Table 1. <i>European Heart Journal</i> , 2016, 37, 1321-1324.	1.0	6
88	ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison. <i>International Journal of Cardiology</i> , 2016, 214, 483-484.	0.8	20
89	Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 897-907.	1.1	24
90	The importance of time: Time delays in acute stroke. <i>Cor Et Vasa</i> , 2016, 58, e225-e232.	0.1	6

#	ARTICLE	IF	CITATIONS
91	Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 134, 1603-1612.	1.6	167
92	Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study. <i>Heart and Vessels</i> , 2016, 31, 841-845.	0.5	9
93	Two-year follow-up after bioresorbable vascular scaffold implantation in STEMI patients – Results from PRAGUE-19 study. <i>International Journal of Cardiology</i> , 2016, 209, 20-21.	0.8	4
94	Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 152-167.	1.4	50
95	P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 229-243.	1.4	46
96	Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension. <i>Hypertension</i> , 2016, 67, 397-403.	1.3	73
97	Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. <i>International Journal of Cardiology</i> , 2016, 203, 708-713.	0.8	5
98	Catheter-based interventions for acute ischaemic stroke. <i>European Heart Journal</i> , 2016, 37, 3081-3089.	1.0	16
99	AHEAD score – Long-term risk classification in acute heart failure. <i>International Journal of Cardiology</i> , 2016, 202, 21-26.	0.8	59
100	Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 282-288.	0.4	3
101	Long-term follow-up after bioresorbable vascular scaffold implantation in STEMI patients: PRAGUE-19 study update. <i>EuroIntervention</i> , 2016, 12, 23-29.	1.4	18
102	Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program. <i>EuroIntervention</i> , 2016, 12, 465-472.	1.4	10
103	Off-pump versus on-pump coronary artery bypass grafting surgery in high-risk patients: PRAGUE-6 trial at 30 days and 1 year. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;</i> , Olomouc, Czechoslovakia, 2016, 160, 263-270.	0.2	15
104	Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: Insights from the international global RESOLUTE program. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 952-958.	0.7	9
105	Positive Influence of Being Overweight/Obese on Long Term Survival in Patients Hospitalised Due to Acute Heart Failure. <i>PLoS ONE</i> , 2015, 10, e0117142.	1.1	18
106	Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. <i>Heart</i> , 2015, 101, 1219-1224.	1.2	15
107	Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations: Table 1. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 232-244.	1.4	13
108	One-Year Clinical and Computed Tomography Angiographic Outcomes After Bioresorbable Vascular Scaffold Implantation During Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002933.	1.4	10

#	ARTICLE	IF	CITATIONS
109	Variants in miRNA Regulating Cardiac Growth Are Not a Common Cause of Hypertrophic Cardiomyopathy. <i>Cardiology</i> , 2015, 130, 137-142.	0.6	3
110	Absorb Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent in ST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity Score Matching Comparison. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 189-197.	1.1	145
111	Serum Dickkopf-1 signaling and calcium deposition in aortic valve are significantly related to the presence of concomitant coronary atherosclerosis in patients with symptomatic calcified aortic stenosis. <i>Journal of Translational Medicine</i> , 2015, 13, 63.	1.8	11
112	Transcatheter aortic valve implantation: long-term clinical outcome and valve durability. <i>Expert Review of Medical Devices</i> , 2015, 12, 529-535.	1.4	9
113	Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. <i>Blood Pressure</i> , 2015, 24, 263-274.	0.7	65
114	Outcomes of patients hospitalized for suspected acute coronary syndrome, in whom the diagnosis was not confirmed: Results from the CZECH-1 and CZECH-2 registries. <i>Cor Et Vasa</i> , 2015, 57, e1-e5.	0.1	0
115	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1718-1719.	1.2	0
116	Potential role of invariant natural killer T cells in outcomes of acute myocardial infarction. <i>International Journal of Cardiology</i> , 2015, 187, 663-665.	0.8	7
117	Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. <i>New England Journal of Medicine</i> , 2015, 372, 1389-1398.	13.9	536
118	Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST-Elevation Myocardial Infarction (ACCOAST) study. <i>American Heart Journal</i> , 2015, 170, 1025-1032.e2.	1.2	17
119	Direct Catheter-Based Thrombectomy for Acute Ischemic Stroke. <i>Journal of the American College of Cardiology</i> , 2015, 66, 487-488.	1.2	17
120	Radial versus femoral access for elderly patients with acute coronary syndrome undergoing coronary angiography and intervention: insights from the RIVAL trial. <i>American Heart Journal</i> , 2015, 170, 880-886.	1.2	46
121	Ischaemic stroke and ST-segment elevation myocardial infarction: fast-track single-stop approach. <i>European Heart Journal</i> , 2015, 36, 2348-2355.	1.0	6
122	Absorb bioresorbable stents for the treatment of coronary artery disease. <i>Expert Review of Medical Devices</i> , 2015, 12, 545-557.	1.4	6
123	Randomized Comparison of Renal Denervation Versus Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension. <i>Hypertension</i> , 2015, 65, 407-413.	1.3	178
124	Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions. <i>EuroIntervention</i> , 2015, 11, 650-657.	1.4	5
125	Prevalence and clinical significance of liver function abnormalities in patients with acute heart failure. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2015, 159, 429-436.	0.2	20
126	Eligibility for Renal Denervation. <i>Hypertension</i> , 2014, 63, 1319-1325.	1.3	61

#	ARTICLE	IF	CITATIONS
127	An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. <i>Current Medical Research and Opinion</i> , 2014, 30, 2193-2205.	0.9	7
128	Acute myocardial infarction complicated by shock: outcome analysis based on initial electrocardiogram. <i>Scandinavian Cardiovascular Journal</i> , 2014, 48, 13-19.	0.4	7
129	Corrigendum to: Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. <i>European Heart Journal</i> , 2014, 35, 2697-2697.	1.0	8
130	Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'. <i>European Heart Journal</i> , 2014, 35, 787-794.	1.0	120
131	Resolute zotarolimus-eluting coronary stent system for the treatment of coronary artery disease. <i>Expert Review of Medical Devices</i> , 2014, 11, 247-257.	1.4	1
132	Effect of Prasugrel Pre-Treatment Strategy in Patients Undergoing Percutaneous Coronary Intervention for NSTEMI. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2563-2571.	1.2	64
133	Patterns of Long-term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the <sc>TIMI</sc>â€³8 Coronary Stent Registry. <i>Clinical Cardiology</i> , 2014, 37, 293-299.	0.7	5
134	Performance of the resolute zotarolimusâ€œeluting stent in small vessels. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 17-23.	0.7	25
135	Incidence and Outcomes Associated With Early Heart Failure Pharmacotherapy in Patients With Ongoing Cardiogenic Shock. <i>Critical Care Medicine</i> , 2014, 42, 281-288.	0.4	25
136	Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. <i>European Heart Journal</i> , 2014, 35, 1957-1970.	1.0	275
137	Predictors of complete arrhythmia free survival in patients undergoing surgical ablation for atrial fibrillation. PRAGUE-12 randomized study sub-analysis. <i>International Journal of Cardiology</i> , 2014, 172, 419-422.	0.8	10
138	Reperfusion therapy of acute ischaemic stroke and acute myocardial infarction: similarities and differences. <i>European Heart Journal</i> , 2014, 35, 147-155.	1.0	36
139	Transportation to primary percutaneous coronary intervention, compared with on-site fibrinolysis, is a strong independent predictor of functional status after myocardial infarction: 5-year follow-up of the PRAGUE-2 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014, 3, 105-109.	0.4	1
140	Trends in epidemiology and the treatment of acute coronary syndromes in the Czech Republic: Comparison of the CZECH-1 and CZECH-2 registries. <i>Cor Et Vasa</i> , 2014, 56, e285-e290.	0.1	3
141	Usefulness and Safety of Vorapaxar in Patients With Nonâ€œST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014, 114, 665-673.	0.7	17
142	Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014, 3, 363-372.	0.4	38
143	ECG in patients with acute heart failure can predict in-hospital and long-term mortality. <i>Internal and Emergency Medicine</i> , 2014, 9, 283-291.	1.0	12
144	Acute Revascularization in ST-Segment-Elevation Myocardial Infarction. <i>Current Atherosclerosis Reports</i> , 2014, 16, 412.	2.0	1

#	ARTICLE	IF	CITATIONS
145	Severe Left Ventricular Systolic Dysfunction is Independently Associated with High On-Clopidogrel Platelet Reactivity. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 313-318.	1.0	4
146	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>Europace</i> , 2014, 16, 1655-1673.	0.7	105
147	The incidence and outcomes of acute coronary syndromes in a central European country: Results of the CZECH-2 registry. <i>International Journal of Cardiology</i> , 2014, 173, 204-208.	0.8	29
148	Procedural Volume and Outcomes With Radial or Femoral Access for Coronary Angiography and Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 63, 954-963.	1.2	70
149	Technical and safety aspects of renal denervation. <i>Cor Et Vasa</i> , 2014, 56, e228-e234.	0.1	5
150	Antiplatelet therapy in patients after an acute coronary syndrome. Comparison of the Czech and Slovak Republics. Results of the ATHRO registry. <i>Cor Et Vasa</i> , 2014, 56, e320-e324.	0.1	1
151	Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: Rationale and design of a multicenter randomized study-PRAGUE-15. <i>Cor Et Vasa</i> , 2014, 56, e235-e239.	0.1	9
152	Direct catheter-based thrombectomy in acute ischaemic stroke performed collaboratively by cardiologists, neurologists and radiologists: the single-centre pilot experience (PRAGUE-16 study). <i>EuroIntervention</i> , 2014, 10, 869-875.	1.4	8
153	Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 1-6.	1.0	5
154	THE RELATIONSHIP BETWEEN SHORT AND LONG-TERM ANTIPLATELET THERAPY USE AND STENT THROMBOSIS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION WITH THE RESOLUTE ZOTAROLIMUS-ELUTING STENT. <i>Journal of the American College of Cardiology</i> , 2013, 61, E1862.	1.2	7
155	Protocols of antithrombotic therapy in a University Cardiocenter. <i>Cor Et Vasa</i> , 2013, 55, e201-e206.	0.1	3
156	Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. <i>European Heart Journal</i> , 2013, 34, 2149-2157.	1.0	225
157	Pretreatment with Prasugrel in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2013, 369, 999-1010.	13.9	539
158	Anticoagulation With Otamixaban and Ischemic Events in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1145.	3.8	58
159	Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. <i>American Heart Journal</i> , 2013, 165, 583-590.e1.	1.2	18
160	Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. <i>Lancet, The</i> , 2013, 382, 605-613.	6.3	105
161	Design and Rationale of the PRAGUE-12 Trial: A Large, Prospective, Randomized, Multicenter Trial That Compares Cardiac Surgery With Left Atrial Surgical Ablation With Cardiac Surgery Without Ablation in Patients With Coronary and/or Valvular Heart Disease Plus Atrial Fibrillation. <i>Clinical Cardiology</i> , 2013, 36, 1-5.	0.7	10
162	Long-term outcomes of patients receiving zotarolimus-eluting stents in ST elevation myocardial infarction, non-ST elevation acute coronary syndrome, and stable angina: Data from the Resolute program. <i>International Journal of Cardiology</i> , 2013, 168, 3522-3526.	0.8	9

#	ARTICLE	IF	CITATIONS
163	Acute coronary syndromes with ongoing myocardial ischemia (ACS with OMI) versus acute coronary syndromes without ongoing ischemia (ACS without OMI). The new classification of acute coronary syndromes should replace old classification based on ST segment elevation presence or absence-Expert consensus statement of the Czech Society of Cardiology. <i>Cor Et Vasa</i> , 2013, 55, e225-e227.	0.1	6
164	Effect of Radial Versus Femoral Access on Radiation Dose and the Importance of Procedural Volume. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 258-266.	1.1	117
165	Clinical Outcome of Patients With and Without Diabetes Mellitus After Percutaneous Coronary Intervention With the Resolute Zotarolimus-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 357-368.	1.1	81
166	The use of revascularization strategies in patients with acute coronary syndromes admitted to hospitals without catheterization facilities: Results from the ALERT-CZ registry. <i>Cor Et Vasa</i> , 2013, 55, e207-e211.	0.1	8
167	Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. <i>International Journal of Cardiology</i> , 2013, 168, 2510-2517.	0.8	18
168	Clinical Outcomes of the Resolute Zotarolimus-Eluting Stent in Patients With In-Stent Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 905-913.	1.1	21
169	Long-term survival following acute heart failure: The Acute Heart Failure Database Main registry (AHEAD Main). <i>European Journal of Internal Medicine</i> , 2013, 24, 151-160.	1.0	59
170	Risk of in-hospital mortality identified according to the typology of patients with acute heart failure: Classification tree analysis on data from the Acute Heart Failure Database "Main registry. <i>Journal of Critical Care</i> , 2013, 28, 250-258.	1.0	10
171	Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1853-1859.	1.2	89
172	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. <i>New England Journal of Medicine</i> , 2013, 368, 1303-1313.	13.9	695
173	ST elevation myocardial infarction treated with bioresorbable vascular scaffold: rationale and first cases. <i>European Heart Journal</i> , 2013, 34, 2073-2073.	1.0	9
174	Pharmacodynamic Effect of Clopidogrel in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>BioMed Research International</i> , 2013, 2013, 1-3.	0.9	14
175	Real-World Safety and Effectiveness Outcomes of a Zotarolimus-Eluting Stent: Final 3-Year Report of the RESOLUTE International Study. <i>Journal of Interventional Cardiology</i> , 2013, 26, 515-523.	0.5	11
176	Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program. <i>Heart</i> , 2013, 99, 626-633.	1.2	31
177	Prognostic Value of TNF-Related Apoptosis Inducing Ligand (TRAIL) in Acute Coronary Syndrome Patients. <i>PLoS ONE</i> , 2013, 8, e53860.	1.1	41
178	An international survey of clinical practice during primary percutaneous coronary intervention for ST-elevation myocardial infarction with a focus on aspiration thrombectomy. <i>EuroIntervention</i> , 2013, 8, 1143-1148.	1.4	12
179	Primary angioplasty in acute myocardial infarction with right bundle branch block: should new onset right bundle branch block be added to future guidelines as an indication for reperfusion therapy?. <i>European Heart Journal</i> , 2012, 33, 86-95.	1.0	115
180	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012, 33, 2569-2619.	1.0	5,034

#	ARTICLE	IF	CITATIONS
181	Transfer Times and Outcomes in Patients With ST-Segmentâ€“Elevation Myocardial Infarction Undergoing Interhospital Transfer for Primary Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 437-444.	0.9	19
182	Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study. <i>European Heart Journal</i> , 2012, 33, 2644-2652.	1.0	113
183	Stent for Life Initiative: where are we standing and where are we going?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2012, 1, 48-49.	0.4	3
184	Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2012, 366, 20-33.	13.9	701
185	Acute heart failure registry from high-volume university hospital ED: comparing European and US data. <i>American Journal of Emergency Medicine</i> , 2012, 30, 695-705.	0.7	12
186	Circulating osteoprotegerin and Dickkopf-1 changed significantly after surgical aortic valve replacement but remained without any significant differences after transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , 2012, 158, 300-301.	0.8	3
187	TCT-639 Two Year Outcomes Following Implantation of the Resolute Zotarolimus-eluting Stent in Vessels â‰¥2.5 mm Diameter. <i>Journal of the American College of Cardiology</i> , 2012, 60, B186.	1.2	0
188	Uric acid, allopurinol therapy, and mortality in patients with acute heart failureâ€“results of the Acute HEart FAilure Database registry. <i>Journal of Critical Care</i> , 2012, 27, 737.e11-737.e24.	1.0	34
189	Acute myocardial infarction due to the left main coronary artery occlusion: electrocardiographic patterns, angiographic findings, revascularization and in-hospital outcomes. <i>Cor Et Vasa</i> , 2012, 54, e3-e7.	0.1	2
190	Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents. <i>Cor Et Vasa</i> , 2012, 54, e32-e38.	0.1	3
191	Expert consensus statement of the Czech Society of Cardiology and the Czech Society of Hypertension on catheter-based sympathetic renal denervation procedures (RDN) in the Czech Republic. <i>Cor Et Vasa</i> , 2012, 54, e108-e112.	0.1	10
192	Summary of the 2012 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevations. Prepared by the Czech Society of Cardiology. <i>Cor Et Vasa</i> , 2012, 54, e273-e289.	0.1	8
193	High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 349-354.	1.0	17
194	Renal Function Assessed Using Cystatin C and Antiplatelet Efficacy of Clopidogrel Assessed Using the Vasodilator-Stimulated Phosphoprotein Index in Patients Having Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2012, 109, 620-623.	0.7	8
195	One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry. <i>EuroIntervention</i> , 2012, 7, 1181-1188.	1.4	44
196	Implementation of primary angioplasty in Europe: Stent for Life initiative progress report. <i>EuroIntervention</i> , 2012, 8, 35-42.	1.4	45
197	Stent for Life: how this initiative began?. <i>EuroIntervention</i> , 2012, 8, P8-P10.	1.4	20
198	Variable penetration of primary angioplasty in Europe â€“ what determines the implementation rate?. <i>EuroIntervention</i> , 2012, 8, P18-P26.	1.4	8

#	ARTICLE	IF	CITATIONS
199	Gender differences in total cholesterol levels in patients with acute heart failure and its importance for short and long time prognosis. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2012, 156, 21-22.	0.2	10
200	Comparison of outcomes in ST-segment depression and ST-segment elevation myocardial infarction patients treated with emergency PCI : data from a multicentre registry : cardiovascular topic. Cardiovascular Journal of Africa, 2012, 23, 495-500.	0.2	11
201	A Comparison of prasugrel at the time of percutaneous Coronary intervention or as pretreatment at the time of diagnosis in patients with nonâ€“ST-segment elevation myocardial infarction: Design and rationale for the ACCOAST study. American Heart Journal, 2011, 161, 650-656.e1.	1.2	23
202	Design and rationale of the Radial Vs. femoral access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes. American Heart Journal, 2011, 161, 254-260.e4.	1.2	46
203	High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: Results from the Primary Coronary Angioplasty Trialist versus Thrombolysis (PCAT)-2 Collaboration. American Heart Journal, 2011, 161, 500-507.e1.	1.2	36
204	Shock Index: A Simple Clinical Parameter for Quick Mortality Risk Assessment in Acute Myocardial Infarction. Canadian Journal of Cardiology, 2011, 27, 739-742.	0.8	66
205	Does previous hypertension affect outcome in acute heart failure?. European Journal of Internal Medicine, 2011, 22, 591-596.	1.0	7
206	Clopidogrel up-titration versus standard dose in patients with high residual platelet reactivity after percutaneous coronary intervention: A single-center pilot randomised study. International Journal of Cardiology, 2011, 150, 231-232.	0.8	7
207	Platelet-derived chemokines, PF-4 and RANTES, are significantly increased in hemodynamically significant degenerative aortic stenosis. International Journal of Cardiology, 2011, 152, 273-275.	0.8	2
208	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.	1.0	2,767
209	Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry. Critical Care, 2011, 15, R291.	2.5	124
210	Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet, The, 2011, 377, 1409-1420.	6.3	1,759
211	La iniciativa Stent for Life en Europa. Revista Espanola De Cardiologia Suplementos, 2011, 11, 2-5.	0.2	3
212	How to treat patients with ST-elevation acute myocardial infarction and multi-vessel disease?. European Heart Journal, 2011, 32, 396-403.	1.0	85
213	Mortality Implications of Primary Percutaneous Coronary Intervention Treatment Delays: Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 183-192.	0.9	26
214	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal, 2011, 32, 1854-1864.	1.0	343
215	Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study. Acute Cardiac Care, 2011, 13, 116-122.	0.2	43
216	Revaskularizace myokardu. PerkutÃ;nnÃ-koronÃ;rnÃ-intervence a aortokoronÃ;rnÃ-bypass. Cor Et Vasa, 2011, 53, 3-24.	0.1	1

#	ARTICLE	IF	CITATIONS
217	The Bioresorbable Stent in Perspective—How Much of an Advance is It?. <i>Interventional Cardiology Review</i> , 2011, 9, 23.	0.7	1
218	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Journal of Anaesthesiology</i> , 2010, 27, 92-137.	0.7	263
219	Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 203-212.	1.1	37
220	An embolus in the right atrium caught in the Chiari network and resistant to thrombolysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 114-118.	1.0	6
221	A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 158-166.	0.7	55
222	Randomized comparison of endothelial progenitor cells capture stent versus cobalt-chromium stent for treatment of ST-elevation myocardial infarction. Six-month clinical, angiographic, and IVUS follow-up. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 627-631.	0.7	29
223	Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux: The FUTURA/OASIS-8 Randomized Trial. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1339-1349.	3.8	161
224	Renal disease and acute coronary syndrome. <i>Heart</i> , 2010, 96, 86-92.	1.2	17
225	2010 Focused Update of ESC Guidelines on device therapy in heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 1143-1153.	2.9	152
226	Clopidogrel Before Elective Percutaneous Coronary Intervention. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 373-379.	1.0	2
227	Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. <i>European Heart Journal</i> , 2010, 31, 1708-1716.	1.0	63
228	Primary angioplasty vs. thrombolysis: the end of the controversy?. <i>European Heart Journal</i> , 2010, 31, 634-636.	1.0	15
229	Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2010, 363, 930-942.	13.9	681
230	Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness. <i>International Journal of Cardiology</i> , 2010, 144, 255-257.	0.8	13
231	Platelet glycoprotein GP VI 13254C allele is an independent risk factor of premature myocardial infarction. <i>Thrombosis Research</i> , 2010, 125, e61-e64.	0.8	28
232	REVIEW: Stent Thrombosis—Risk Assessment and Prevention. <i>Cardiovascular Therapeutics</i> , 2010, 28, e92-100.	1.1	18
233	2010 Focused Update of ESC Guidelines on device therapy in heart failure. <i>Europace</i> , 2010, 12, 1526-1536.	0.7	297
234	RESISTANCE TO CLOPIDOGREL ASSESSED BY VASP PHOSPHORYLATION IS A NEGATIVE PROGNOSTIC FACTOR IN PATIENTS UNDERGOING ELECTIVE PCI FOR STABLE CORONARY ARTERY DISEASE: ANALYSIS FROM LABORATORY SUBSTUDY OF PRAGUE 8 TRIAL. <i>Journal of the American College of Cardiology</i> , 2010, 55, A98.E926.	1.2	2

#	ARTICLE	IF	CITATIONS
235	Platelet gene polymorphisms and risk of bleeding in patients undergoing elective coronary angiography: A genetic substudy of the PRAGUE-8 trial. <i>Atherosclerosis</i> , 2010, 212, 548-552.	0.4	22
236	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. <i>Lancet, The</i> , 2010, 376, 1233-1243.	6.3	725
237	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2010, 31, 2501-2555.	1.0	2,649
238	Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2010, 12, 1360-1420.	0.7	1,360
239	Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. <i>European Heart Journal</i> , 2010, 31, 943-957.	1.0	548
240	Treatment of ST elevation acute myocardial infarction in Europe. <i>Cor Et Vasa</i> , 2010, 52, 22-23.	0.1	0
241	Measuring of platelet activity and efficacy of antiplatelet therapy. <i>Cor Et Vasa</i> , 2010, 52, 15-20.	0.1	0
242	Aspirin resistance after coronary artery bypass grafting. <i>Cor Et Vasa</i> , 2010, 52, 52-58.	0.1	0
243	Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel. <i>Vascular Health and Risk Management</i> , 2009, 5, 475.	1.0	5
244	Intravenous Platelet Blockade with Cangrelor during PCI. <i>New England Journal of Medicine</i> , 2009, 361, 2330-2341.	13.9	560
245	Low Prevalence and Variable Clinical Presentation of Troponin I and Troponin T Gene Mutations in Hypertrophic Cardiomyopathy. <i>Genetic Testing and Molecular Biomarkers</i> , 2009, 13, 647-650.	0.3	6
246	Incidence of and Outcomes Associated With Ventricular Tachycardia or Fibrillation in Patients Undergoing Primary Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1779.	3.8	238
247	Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. <i>European Heart Journal</i> , 2009, 30, 2019-2028.	1.0	130
248	Clopidogrel resistance "Live" \approx 1/2 the risk of stent thrombosis should be evaluated before procedures. <i>Thrombosis Journal</i> , 2009, 7, 6.	0.9	5
249	1-Year Survival in a Randomized Trial of Facilitated Reperfusion. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 909-916.	1.1	59
250	Early versus Delayed Invasive Intervention in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2009, 360, 2165-2175.	13.9	748
251	Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. <i>American Heart Journal</i> , 2009, 157, 763-770.	1.2	28
252	Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines. <i>Journal of the American College of Cardiology</i> , 2009, 54, 468-476.	1.2	67

#	ARTICLE	IF	CITATIONS
253	Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. <i>Lancet</i> , The, 2009, 374, 787-795.	6.3	123
254	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Heart Journal</i> , 2009, 30, 2769-2812.	1.0	735
255	High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 257-262.	0.5	13
256	Factors Influencing Clopidogrel Efficacy in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention: Statin's Advantage and the Smoking "Paradox". <i>Journal of Cardiovascular Pharmacology</i> , 2009, 53, 368-372.	0.8	25
257	"Stent 4 Life"-Targeting PCI at all who will benefit the most. <i>EuroIntervention</i> , 2009, 4, 555-557.	1.4	80
258	"Stent 4 Life" targeting PCI at all who will benefit the most. A joint project between EAPCI, Euro-PCR, EUCOMED and the ESC Working Group on Acute Cardiac Care. <i>EuroIntervention</i> , 2009, 4, 555, 557.	1.4	7
259	How to set up an effective national primary angioplasty network: lessons learned from five European countries. <i>EuroIntervention</i> , 2009, 5, 299, 301-309.	1.4	14
260	Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2008, 29, 2276-2315.	1.0	2,645
261	Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery: Results from the prospective randomized trial PRAGUE 11 "Coronary Artery Bypass and REactivity of Thrombocytes (CABARET)". <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 136, 1054-1060.	0.4	42
262	Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2028-2033.	1.2	314
263	Design and rationale of CURRENT-OASIS 7: A randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. <i>American Heart Journal</i> , 2008, 156, 1080-1088.e1.	1.2	140
264	Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. <i>European Heart Journal</i> , 2008, 29, 1495-1503.	1.0	132
265	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. <i>European Heart Journal</i> , 2008, 29, 2909-2945.	1.0	2,128
266	Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2008, 118, 2038-2046.	1.6	98
267	Facilitated PCI in Patients with ST-Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2008, 358, 2205-2217.	13.9	596
268	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. <i>European Journal of Heart Failure</i> , 2008, 10, 933-989.	2.9	1,893
269	The Time Has Come for New, More Precise Guidelines in the Treatment of High-Risk Acute Coronary Syndromes With Heparin. <i>Circulation Journal</i> , 2008, 72, 1674-1679.	0.7	2
270	Next Day Discharge After Successful Primary Angioplasty for Acute ST Elevation Myocardial Infarction An Open Randomized Study "Prague-5". <i>International Heart Journal</i> , 2008, 49, 653-659.	0.5	36

#	ARTICLE	IF	CITATIONS
271	The additional value of patient-reported health status in predicting 1-year mortality after invasive coronary procedures: a report from the Euro Heart Survey on Coronary Revascularisation. <i>Heart</i> , 2007, 93, 339-344.	1.2	47
272	Myocardial positive pre-ejection velocity accurately detects presence of viable myocardium, predicts recovery of left ventricular function and bears a prognostic value after surgical revascularization. <i>European Heart Journal</i> , 2007, 28, 1366-1373.	1.0	19
273	Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years' follow-up of the PRAGUE-2 trial. <i>European Heart Journal</i> , 2007, 28, 679-684.	1.0	88
274	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) <i>Tj ETQq0 0 0.igBT /Overlock 10 T</i>		
275	2007 Guidelines for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1105-1187.	0.3	4,778
276	Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2007, 116, 2634-2653.	1.6	2,755
277	Near-normal coronary angiography in a patient, who is entirely asymptomatic 24 years after successful intracoronary thrombolysis for ST elevation myocardial infarction. Follow-up of the historically first Czech intracoronary thrombolysis patient. <i>Acute Cardiac Care</i> , 2007, 9, 239-242.	0.2	2
278	THE TIME HAS COME FOR NEW, MORE PRECISE GUIDELINES IN THE TREATMENT OF HIGH RISK ACUTE CORONARY SYNDROMES WITH HEPARIN. <i>Chest</i> , 2007, 132, 545A.	0.4	0
279	The comparison of platelet activity between patients with patent vs. occluded coronary artery bypass grafts. <i>Thrombosis Research</i> , 2007, 120, 523-529.	0.8	3
280	Prevalence of stress-induced myocardial stunning (Tako-Tsubo cardiomyopathy) among patients undergoing emergency coronary angiography for suspected acute myocardial infarction. <i>International Journal of Cardiology</i> , 2007, 120, 411-413.	0.8	20
281	The incidence, treatment strategies and outcomes of acute coronary syndromes in the reperfusion network of different hospital types in the Czech Republic: Results of the Czech evaluation of acute coronary syndromes in hospitalized patients (CZECH) registry. <i>International Journal of Cardiology</i> , 2007, 119, 212-219.	0.8	48
282	Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) <i>Tj ETQq0 0 0.igBT /Overlock 10 T</i>		
283	Comparison of cationic propyl gallate and adenosine diphosphate for the measurement of aspirin effectivity with optical aggregometry. <i>Translational Research</i> , 2007, 150, 246-252.	2.2	3
284	Severe Left Ventricular Dyssynchrony Is Associated With Poor Prognosis in Patients With Moderate Systolic Heart Failure Undergoing Coronary Artery Bypass Grafting. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1315-1323.	1.2	74
285	Intracoronary Injection of Autologous Bone Marrow-Derived Mononuclear Cells in Patients With Large Anterior Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2373-2374.	1.2	87
286	The impact of age and Killip class on outcomes of primary percutaneous coronary intervention. Insight from the PRAGUE-1 and -2 trials and registry. <i>EuroIntervention</i> , 2007, 2, 481-6.	1.4	6
287	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2006, 28, 1462-1536.	1.0	1,617
288	Complications after intracoronary stem cell transplantation in idiopathic dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2006, 111, 178-179.	0.8	16

#	ARTICLE	IF	CITATIONS
289	Intracoronary transplantation of bone marrow stem cells: background, techniques, and limitations. Country Review Ukraine, 2006, 8, H16-H22.	0.8	10
290	Cellular therapy of coronary heart disease: a review of concepts, limitations, prospects. Part Two. Stem cells, prospects of cellular therapy. Cor Et Vasa, 2006, 48, 234-241.	0.1	0
291	Left ventricular remodelling adaptation or maladaptation?. Cor Et Vasa, 2006, 48, 441-446.	0.1	0
292	ORIGINAL RESEARCHâ€”PHARMACOTHERAPY: Hemodynamic Effects of Sildenafil Citrate and Isosorbide Mononitrate in Men with Coronary Artery Disease and Erectile Dysfunction. Journal of Sexual Medicine, 2005, 2, 407-414.	0.3	16
293	Routine vs Selective Invasive Strategies in Patients With Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2005, 293, 2908.	3.8	717
294	Early Tissue Distribution of Bone Marrow Mononuclear Cells After Transcoronary Transplantation in a Patient With Acute Myocardial Infarction. Circulation, 2005, 112, e63-5.	1.6	59
295	Influence of Primary Coronary Intervention on Myocardial Collagen Metabolism and Left Ventricle Remodeling Predicted by Collagen Metabolism Markers. International Heart Journal, 2005, 46, 949-959.	0.5	9
296	Diurnal Variation of Soluble E- and P-Selectin, and Intercellular Adhesion Molecule-1 in Patients with and without Coronary Artery Disease. Cardiology, 2004, 102, 194-199.	0.6	16
297	One-Year Coronary Bypass Graft Patency. Circulation, 2004, 110, 3418-3423.	1.6	243
298	Bleeding events with abciximab in acute coronary syndromes without early revascularization: an analysis of GUSTO IVâ€”ACS. American Heart Journal, 2004, 147, 865-873.	1.2	37
299	Off-pump versus on-pump coronary surgery: final results from a prospective randomized study Prague-4. Annals of Thoracic Surgery, 2004, 77, 789-793.	0.7	184
300	Acute Myocardial Infarction Complicated by Early Onset of Heart Failure:. Journal of Interventional Cardiology, 2003, 16, 201-208.	0.5	9
301	Reimplantation of anomalous right coronary artery arising from the pulmonary trunk leading to normal coronary flow reserve late after surgery. Annals of Thoracic Surgery, 2003, 76, 1287-1289.	0.7	16
302	Inter-hospital Transport for Primary Angioplasty Does Not Compromise Left Ventricular Function. International Heart Journal, 2003, 44, 313-322.	0.6	2
303	Routine immediate extubation for off-pump coronary artery bypass grafting without thoracic epidural analgesia. Annals of Thoracic Surgery, 2002, 74, 1544-1547.	0.7	82
304	Systematic adjudication of myocardial infarction end-points in an international clinical trial. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 180.	1.5	66
305	Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 187.	1.5	78
306	Pericardial Effusion as a Consequence of Acute Myocardial Infarction. Echocardiography, 1999, 16, 317-320.	0.3	4

#	ARTICLE	IF	CITATIONS
307	Pericardial Involvement During the Course of Myocardial Infarction. Chest, 1995, 108, 89-93.	0.4	32
308	Electrocardiographic changes can precede the development of myocardial hypertrophy in the setting of hypertrophic cardiomyopathy. International Journal of Cardiology, 1989, 23, 335-341.	0.8	16
309	Effect of papaverine administration on myocardial echocontrast distribution. American Heart Journal, 1987, 114, 1248-1249.	1.2	10
310	Echocardiographic picture in diabetes mellitus.. International Heart Journal, 1984, 25, 969-977.	0.6	10